{"title":"Whole Exome Sequencing Reveals Novel Genetic Variants Associated with Atrial Septal Defect in a Tibetan Patient Cohort.","authors":"Hongwei Li, Yongjun He, Zhengyao Cai, Qianqiu Che, Yong Wu, Mingshuang Zhou, Zeng He, Liming Zhao","doi":"10.2147/PGPM.S525556","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Atrial septal defect (ASD) is a common congenital heart defect with incompletely understood genetic underpinnings, particularly in specific ethnic groups. This study aimed to identify novel genetic variants related to ASD within the Tibetan population using whole exome sequencing (WES).</p><p><strong>Methods: </strong>Genomic DNA was extracted from blood samples of 17 Tibetan ASD patients. WES was performed using the Illumina HiSeq platform. After rigorous filtering, detection, and annotation of single nucleotide variations (SNVs) and insertion-deletions (InDels), potentially pathogenic variants were prioritized. Functional impact predictions were conducted using SIFT, PolyPhen V2, MutationTaster, and CADD databases to identify variants likely contributing to ASD etiology.</p><p><strong>Results: </strong>We identified nine high-confidence candidate variants in Tibetan ASD patients, including rs145116532 (<i>ALKAL1</i>, c.287G >A: p. R96Q), rs374798430 (<i>AVL9</i>, c.1267G >A: p.D423N), rs138933092 (<i>C5</i>, c.4432C >T: p.R1478W), rs141638421 (<i>CRYAB</i>, c.470G>A: p.R157H), rs147287319 (<i>DOCK8</i>, c.989G>A: c.1193G>A: p.R330Q, p.R398Q), rs141616597 (<i>NTN3</i>, c.1243C>T: p.R415C), rs117506395 (<i>PIWIL1</i>, c.2207C>T: p.T736M), rs142533677 (<i>PLEKHG4</i>, c.2246G>A: p.R749Q), and rs118203532 (<i>TSC1</i>, c.1460C>G: p.S487C). Function annotation further suggested potential associations of <i>C5, CRYAB, PIWIL1</i>, and <i>TSC1</i> with congenital heart diseases.</p><p><strong>Conclusion: </strong>This first WES-based study of Tibetan ASD patients reveals population-specific genetic determinants. The nine novel candidate variants, particularly in <i>C5, CRYAB, PIWIL1</i>, and <i>TSC1</i>, provide preliminary insights into ASD etiology in high-altitude populations and highlight potential targets for future diagnostic biomarker development.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":"18 ","pages":"239-250"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433626/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics & Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PGPM.S525556","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的:房间隔缺损(ASD)是一种常见的先天性心脏缺陷,其遗传基础尚不完全清楚,特别是在特定的种族群体中。WES采用Illumina HiSeq平台进行。经过严格的筛选、检测和注释单核苷酸变异(snv)和插入缺失(InDels),潜在的致病变异被优先考虑。使用SIFT、PolyPhen V2、MutationTaster和CADD数据库进行功能影响预测,以确定可能导致ASD病因的变异。287G >A: p. R96Q), rs374798430 (AVL9, c.1267G >A: p. d423n), rs138933092 (C5, c.4432C >A: p. r1478w), rs141638421 (CRYAB, c.470G>A: p. r157h), rs147287319 (DOCK8, c.989G>A: c.1193G>A: p. r330q, p. r398q), rs141616597 (NTN3, c.1243C>T: p. r415c), rs117506395 (pik1, c.2207C>T: p. r736m), rs142533677 (PLEKHG4, c.2246G>A: p. r749q), rs118203532 (TSC1, c.1460C>G: p. s487c)。功能注释进一步提示C5、CRYAB、PIWIL1和TSC1与先天性心脏病的潜在关联。9个新的候选变异,特别是C5、CRYAB、PIWIL1和TSC1,为高海拔人群的ASD病因学提供了初步的见解,并突出了未来诊断生物标志物开发的潜在靶点。
Whole Exome Sequencing Reveals Novel Genetic Variants Associated with Atrial Septal Defect in a Tibetan Patient Cohort.
Objective: Atrial septal defect (ASD) is a common congenital heart defect with incompletely understood genetic underpinnings, particularly in specific ethnic groups. This study aimed to identify novel genetic variants related to ASD within the Tibetan population using whole exome sequencing (WES).
Methods: Genomic DNA was extracted from blood samples of 17 Tibetan ASD patients. WES was performed using the Illumina HiSeq platform. After rigorous filtering, detection, and annotation of single nucleotide variations (SNVs) and insertion-deletions (InDels), potentially pathogenic variants were prioritized. Functional impact predictions were conducted using SIFT, PolyPhen V2, MutationTaster, and CADD databases to identify variants likely contributing to ASD etiology.
Results: We identified nine high-confidence candidate variants in Tibetan ASD patients, including rs145116532 (ALKAL1, c.287G >A: p. R96Q), rs374798430 (AVL9, c.1267G >A: p.D423N), rs138933092 (C5, c.4432C >T: p.R1478W), rs141638421 (CRYAB, c.470G>A: p.R157H), rs147287319 (DOCK8, c.989G>A: c.1193G>A: p.R330Q, p.R398Q), rs141616597 (NTN3, c.1243C>T: p.R415C), rs117506395 (PIWIL1, c.2207C>T: p.T736M), rs142533677 (PLEKHG4, c.2246G>A: p.R749Q), and rs118203532 (TSC1, c.1460C>G: p.S487C). Function annotation further suggested potential associations of C5, CRYAB, PIWIL1, and TSC1 with congenital heart diseases.
Conclusion: This first WES-based study of Tibetan ASD patients reveals population-specific genetic determinants. The nine novel candidate variants, particularly in C5, CRYAB, PIWIL1, and TSC1, provide preliminary insights into ASD etiology in high-altitude populations and highlight potential targets for future diagnostic biomarker development.
期刊介绍:
Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.
In particular, emphasis will be given to:
Genomic and proteomic profiling
Genetics and drug metabolism
Targeted drug identification and discovery
Optimizing drug selection & dosage based on patient''s genetic profile
Drug related morbidity & mortality intervention
Advanced disease screening and targeted therapeutic intervention
Genetic based vaccine development
Patient satisfaction and preference
Health economic evaluations
Practical and organizational issues in the development and implementation of personalized medicine programs.